Kevin R. Lind
2023 - Longboard Pharmaceuticals
In 2023, Kevin R. Lind earned a total compensation of $2.1M as President and Chief Executive Officer at Longboard Pharmaceuticals, a 36% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $442,860 |
|---|---|
| Option Awards | $986,934 |
| Salary | $610,000 |
| Other | $14,010 |
| Total | $2,053,804 |
Lind received $986.9K in option awards, accounting for 48% of the total pay in 2023.
Lind also received $442.9K in non-equity incentive plan, $610K in salary and $14K in other compensation.
Rankings
In 2023, Kevin R. Lind's compensation ranked 496th out of 2,785 executives tracked by ExecPay. In other words, Lind earned more than 82.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 496 out of 2,785 | 82nd |
Division Manufacturing | 285 out of 1,525 | 81st |
Major group Chemicals And Allied Products | 199 out of 864 | 77th |
Industry group Drugs | 196 out of 827 | 76th |
Industry Pharmaceutical Preparations | 123 out of 592 | 79th |
Source: SEC filing on April 12, 2024.
Lind's colleagues
We found two more compensation records of executives who worked with Kevin R. Lind at Longboard Pharmaceuticals in 2023.